Is Enclomiphene Actually Dangerous?

Your body runs testosterone production through a communication chain that starts in your brain and ends in your testes, and the whole system depends on feedback loops that tell each part of the chain how hard to work.

The hypothalamus releases something called GnRH, which is a signaling hormone that tells the pituitary gland to release LH and FSH. LH travels down to the testes and tells them to produce testosterone. As testosterone rises, some of it converts to estradiol, and that estradiol travels back up to the hypothalamus and pituitary and signals them to slow down. The whole system quiets itself when it senses enough hormone in circulation.

That feedback mechanism is exactly what enclomiphene targets.

Enclomiphene sits at the estrogen receptors in the hypothalamus and pituitary and blocks them, so those receptors never receive the slowdown signal. The brain reads the situation as low estrogen, decides it needs to drive harder, and sends stronger signals down to the testes to produce more testosterone. The testes respond because they are capable of producing more. The brain just needed a reason to ask.

That matters because most drugs used for low testosterone work by replacing the signal entirely. Testosterone injections, gels, and patches put testosterone directly into circulation, which the body reads as an abundance of hormone, and so it shuts down its own production almost completely. Enclomiphene does the opposite. It amplifies the natural signal instead of replacing it.

Now here is where most of the confusion about enclomiphene comes from.

Clomiphene, the drug sold as Clomid, has been used off-label in men for decades, and it has a real side effect profile. Mood swings, vision disturbances, decreased libido, rising estradiol. These effects are well documented and have made a lot of clinicians and patients reluctant to use anything in the same category.

But clomiphene is not enclomiphene. Clomiphene is a mixture of two molecules, something called isomers, which are chemically similar structures that behave differently in the body. Clomiphene is roughly 62% enclomiphene and 38% of a second isomer called zuclomiphene. Enclomiphene blocks estrogen receptors, which is the effect you want. Zuclomiphene activates estrogen receptors, which is the effect you do not want.

The half-life difference between these two molecules explains a lot. Enclomiphene clears the body in about 10 hours. Zuclomiphene stays in circulation for days, sometimes weeks with repeated dosing, and while it is there it is continuously activating estrogen receptors throughout the body, which drives up estradiol, destabilizes mood, suppresses libido, and in some cases contributes to the visual disturbances that Clomid became associated with.

So the fear around enclomiphene is largely borrowed from zuclomiphene, and the data makes this distinction very clear.

A 2024 study out of Baylor compared the two compounds directly in 66 men. Forty-seven percent of the men on clomiphene reported side effects. On enclomiphene, that number dropped to 13.8%. Mood changes went from 9.1% on clomiphene to 0% on enclomiphene. Decreased libido went from 33.3% down to 8.6%. Estradiol actually decreased with enclomiphene while it rose with clomiphene, which reflects exactly what you would expect when you remove the zuclomiphene component from the equation.

A 2025 meta-analysis pooled data from 10 randomized controlled trials covering 819 patients and found that while 21% of participants experienced some form of adverse event across the combined studies, none of the adverse events were classified as severe. That is a meaningful distinction. Mild side effects in a fifth of users is a very different picture than the dangerous drug profile that circulates on social media.

The efficacy data runs alongside the safety data and tells a consistent story.

A 2013 study gave 44 men 25 milligrams of enclomiphene daily for six weeks and measured testosterone at 604 ng/dL on average at that dose, with no meaningful changes in thyroid hormones, cortisol, ACTH, lipids, or bone markers. The drug raised testosterone through the HPG axis without disturbing other hormonal systems.

A 2014 study followed 124 men for three months and found testosterone rose from a baseline of 217 ng/dL up to 472 ng/dL on a 12.5 milligram dose, and sperm counts held steady at a mean of 176 million per milliliter. That last point matters because testosterone replacement therapy typically suppresses sperm production significantly, which is a real concern for men who want to preserve fertility. Enclomiphene raises testosterone through the natural signaling pathway, so the testes stay active and sperm production continues.

There are legitimate gaps in the current evidence worth naming directly.

The longest published follow-up data runs to about six months, so nobody knows what the long-term picture looks like beyond that window. The branded version of enclomiphene, called Androxal, was rejected by the FDA, though the rejection was based on study design concerns and not on safety signals from the data. And because enclomiphene is mostly available through compounding pharmacies rather than a standardized pharmaceutical product, the concentration and purity of what a patient actually receives can vary, which introduces variability that clinical trials do not capture.

None of those gaps mean the drug is dangerous. They mean the evidence has limits and those limits should be acknowledged.

What the published data shows is that enclomiphene and zuclomiphene are not the same drug, they are not even close to the same drug in terms of mechanism, half-life, or receptor activity, and the side effect profile that made Clomid a complicated option for many men traces primarily to the isomer that enclomiphene does not contain.

The real risk with enclomiphene is not in the pharmacology. It is in making a decision about a compound without understanding what it actually is and what it is actually doing, because the version of this drug that most people are afraid of exists in a different molecule entirely.

---

References

1. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;139:1979-1987. Finding: Side effects: clomiphene 47% vs enclomiphene 13.8% p=0.001. Mood changes: 9.1% vs 0% p=0.03. Decreased libido: 33.3% vs 8.6% p=0.001. Estradiol decreased with enclomiphene, increased with clomiphene p=0.001. Source
2. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025. Finding: 10 RCTs, 819 patients. SERM therapy increased total testosterone by 273.76 ng/dL vs placebo p<0.01. 21% experienced adverse events; none were severe. Source
3. Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism. BJU International. 2013;1128:1188-1200. Finding: 44 men, 6 weeks. 25 mg enclomiphene averaged 604 ng/dL testosterone. No effects on TSH, ACTH, cortisol, lipids, or bone markers. Source
4. Wiehle R, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility. 2014;1023:720-727. Finding: 124 men, 3 months. Testosterone rose from 217 to 472 ng/dL 12.5 mg. Sperm counts preserved mean 176 million/mL. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness